Key result
Low CD9+ B cell frequency is linked to higher bronchiolitis obliterans syndrome risk after lung transplant.
Why the study?
Bronchiolitis obliterans syndrome limits long-term survival after lung transplantation, and specific B cell populations may be associated with graft acceptance but require further characterization.
Does the frequency of blood CD9+ B cells predict the development of bronchiolitis obliterans syndrome in lung transplant recipients?
Cohort
Does the frequency of blood CD9+ B cells predict the development of bronchiolitis obliterans syndrome in lung transplant recipients?
Effect estimate: AUC 0.836
CD9-expressing B cells may serve as a novel predictive biomarker for bronchiolitis obliterans syndrome-free survival after lung transplantation.
Low CD9+ B-cell frequency was associated with higher BOS incidence; hypothesis-generating for biomarker-guided risk stratification after lung transplant.
Bronchiolitis obliterans syndrome is the main limitation for long-term survival after lung transplantation. Some specific B cell populations are associated with long-term graft acceptance. We aimed to monitor the B cell profile during early development of bronchiolitis obliterans syndrome after lung transplantation. The B cell longitudinal profile was analyzed in peripheral blood mononuclear cells from patients with bronchiolitis obliterans syndrome and patients who remained stable over 3 years of follow-up. CD24 hi CD38 hi transitional B cells were increased in stable patients only, and reached a peak 24 months after transplantation, whereas they remained unchanged in patients who developed a bronchiolitis obliterans syndrome. These CD24 hi CD38 hi transitional B cells specifically secrete IL-10 and express CD9. Thus, patients with a total CD9 + B cell frequency below 6.6% displayed significantly higher incidence of bronchiolitis obliterans syndrome (AUC = 0.836, PPV=0.75, NPV=1). These data are the first to associate IL-10-secreting CD24 hi CD38 hi transitional B cells expressing CD9 with better allograft outcome in lung transplant recipients. CD9-expressing B cells appear as a contributor to a favorable environment essential for the maintenance of long-term stable graft function and as a new predictive biomarker of bronchiolitis obliterans syndrome–free survival.
No takes yet. Share an insight, caveat, or question.
Brosseau et al. (2019) conducted a cohort in Bronchiolitis obliterans syndrome after lung transplantation. Total CD9+ B cell frequency < 6.6% vs. Total CD9+ B cell frequency ≥ 6.6% was evaluated on Incidence of bronchiolitis obliterans syndrome (AUC 0.836). A total CD9+ B cell frequency below 6.6% in lung transplant recipients was associated with a significantly higher incidence of bronchiolitis obliterans syndrome (AUC = 0.836, PPV=0.75, NPV=1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: